micronized niclosamide (FW-420)
/ Entero Therap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 03, 2022
First Wave BioPharma Announces Poster Presentation at the 2022 Digestive Disease Week (DDW) Conference
(GlobeNewswire)
- "First Wave BioPharma, Inc...announced today that an abstract entitled, 'Niclosamide Enemas, A Safe And Effective Treatment In Mild To Moderate Ulcerative Proctitis/Proctosigmoiditis: Results From An Open Label Study,' has been accepted for a poster presentation at the 2022 Digestive Disease Week Conference (DDW 2022). The conference is taking place May 21-24, 2022, in San Diego, California."
P1/2 data • Gastrointestinal Disorder • Immunology • Inflammation • Ulcerative Colitis
October 19, 2021
First Wave BioPharma Announces FDA Clearance of IND Application for Phase 2a PASSPORT Trial of FW-ICI-AC as Treatment for Immune Checkpoint Inhibitor-Associated Colitis
(GlobeNewswire)
- "First Wave BioPharma, Inc...announced today that the U.S. Food and Drug Administration (FDA) has reviewed the Investigational New Drug (IND) application and provided a 'Study May Proceed' letter for the Company’s Phase 2a PASSPORT trial investigating FW-ICI-AC as a treatment for Grade 1 and Grade 2 colitis and diarrhea in oncology patients receiving treatment with immune checkpoint inhibitors (ICIs)."
New P2a trial • Inflammatory Bowel Disease • Ulcerative Colitis
May 31, 2021
[VIRTUAL] AzurRx BioPharma
(BIO 2021)
- "The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-420, for grade 1 Immune Checkpoint Inhibitor-Associated Colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California."
Cystic Fibrosis • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immune Modulation • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Oncology • Pancreatitis • Pulmonary Disease • Respiratory Diseases
1 to 3
Of
3
Go to page
1